Novo Nordisk A/S (LON:0QIU)
London · Delayed Price · Currency is GBP · Price in DKK | Market Cap | 162.55B -29.3% |
| Revenue (ttm) | 38.30B +8.1% |
| Net Income | 14.25B +16.6% |
| EPS | 3.20 +16.8% |
| Shares Out | n/a |
| PE Ratio | 11.41 |
| Forward PE | 16.18 |
| Dividend | 1.37 (3.74%) |
| Ex-Dividend Date | Mar 27, 2026 |
| Volume | 234,418 |
| Open | 320.30 |
| Previous Close | 320.55 |
| Day's Range | 319.45 - 326.20 |
| 52-Week Range | 224.55 - 465.00 |
| Beta | 0.24 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 5, 2026 |
About Novo Nordisk
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products. It operates through two segments, Obesity and Diabetes Care, and Rare Disease. The Obesity and Diabetes care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides NovoPen 6 and NovoPen Echo Pl... [Read more]
Financial Performance
In 2025, Novo Nordisk's revenue was 309.06 billion, an increase of 6.43% compared to the previous year's 290.40 billion. Earnings were 102.43 billion, an increase of 1.43%.
Financial numbers in DKK Financial StatementsNews
Novo Nordisk announces new data from phase 3 FRONTIER4 study of denecimig
Novo Nordisk (NVO) unveiled new data from the phase 3 FRONTIER4 extension study evaluating the long-term safety and efficacy of investigational denecimig subcutaneous prophylaxis in children, adolesce...
Novo Nordisk’s Hemophilia Drug Delivers Strong Results, but Analysts See 10% Downside for NVO Stock
Novo Nordisk A/S ($NVO), a global healthcare company best known for its diabetes and obesity treatments, reported new phase 3 data that could strengthen its position in the hemophilia market.
3 Dividend Stocks That Are No-Brainer Buys Heading Into the Second Half of 2026
Novo Nordisk is helping lead the way in the GLP-1 weight-loss niche. Realty Income is a real estate giant built to pay reliable dividends.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical believes a tiny implant placed under the skin could help address the biggest issue with blockbuster GLP-1s: keeping patients on treatment to maintain their weight loss. The biotech comp...
India gets world's first once-a-week insulin: All about Novo Nordisk's Awiqli
India News: India has become one of the first countries in the world to introduce Awiqli, the world's first once-a-week basal insulin approved for clinical use, o.
Novo Nordisk launches weekly insulin Awiqli in India as diabetes burden rises
Danish drugmaker Novo Nordisk launched its weekly basal insulin injection, Awiqli, in India on Thursday, where diabetes rates are among the highest in the world.
NVO: Novo Nordisk Updates Semaglutide Label in Singapore
NVO: Novo Nordisk Updates Semaglutide Label in Singapore
Novo Nordisk announces updated semaglutide label in Singapore
Novo Nordisk (NVO) announced an update to the Singapore label for semaglutide, approved in Singapore as Wegovy injection, incorporating clinical evidence from the STEP UP trial in adults living with…
Eli Lilly and Novo Nordisk Are Fine -- but These 2 Stocks Could Be an Even Better Way to Invest in the GLP-1 Boom
Don't sleep on these medical device leaders.
3 Reasons to Buy Novo Nordisk Stock
Novo Nordisk has several pipeline candidates that will help improve its position in its core market. The company's margins are excellent compared to its peers.
Why This Novo Nordisk Rival Just Soared Near A Profit-Taking Zone
Agios stock skyrocketed closer to a profit-taking zone Tuesday after the FDA assigned its sickle cell drug a speedy review.
Vivani Medical (VANI) Partners with Novo Nordisk for Semaglutide Implant Study
Vivani Medical (VANI) Partners with Novo Nordisk for Semaglutide Implant Study
Vivani Medical In Deal With Novo Nordisk To Evaluate Semaglutide Drug Implant NPM-139
(RTTNews) - On Tuesday, Vivani Medical, Inc. (VANI), a biopharmaceutical company focused on ultra long-acting drug implants, announced a new agreement, under which Novo Nordisk B A/S (NVO) will evalua...
Vivani Medical enters pact with Novo Nordisk to evaluate NPM-139
Vivani Medical (VANI) announced the signing of a new agreement with Novo Nordisk (NVO) to enable Novo Nordisk to evaluate NPM-139, the company’s semaglutide drug implant. NPM-139, which utilizes Vivan...
Novo Nordisk price target raised to DKK 300 from DKK 280 at HSBC
HSBC raised the firm’s price target on Novo Nordisk (NVO) to DKK 300 from DKK 280 and keeps a Hold rating on the shares. In a sector note on Healthcare,…
Wegovy weight-loss pill goes on sale at UK high street and online pharmacies
Thousands of people begin receiving their first deliveries of the medication made by Novo Nordisk The once-a-day Wegovy weight-loss pill has gone on sale at high street and online pharmacies in the UK...
Novo Nordisk (NVO) Seeks Supplier Discounts to Boost Competitiveness
Novo Nordisk (NVO) Seeks Supplier Discounts to Boost Competitiveness
Medicare Expands Access to GLP-1 Drugs, Boosting Eli Lilly (LLY) and Novo Nordisk (NVO)
Medicare Expands Access to GLP-1 Drugs, Boosting Eli Lilly (LLY) and Novo Nordisk (NVO)
Eli Lilly (LLY) and Novo Nordisk (NVO) to Benefit from New Medicare GLP-1 Program
Eli Lilly (LLY) and Novo Nordisk (NVO) to Benefit from New Medicare GLP-1 Program
Novo Nordisk Stock (NVO) Rises as Medicare Starts Covering Obesity Drugs
Novo Nordisk’s ($NVO) shares rose about 1% during Wednesday’s pre-market session as the U.S. Medicare health insurance program began covering obesity drugs for millions of older Americans. This is exp...
Medicare Expands Coverage for GLP-1 Weight Loss Drugs Boosting Novo Nordisk (NVO)
Medicare Expands Coverage for GLP-1 Weight Loss Drugs Boosting Novo Nordisk (NVO)
Medicare will start covering obesity drugs for the first time. Here's what patients should know
Starting Wednesday, eligible seniors with Medicare coverage can access GLP-1s for obesity with a copay of just $50 per month through a temporary program called Bridge. The move could unlock a vast new...
Novo Nordisk: A Buy After The 340B Reset, With The Pill As Optionality
Novo Nordisk: A Buy After The 340B Reset, With The Pill As Optionality
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Millions of older Americans in Medicare are about to gain access to obesity drugs through Medicare's new Bridge demonstration program for a monthly copay of just $50. But many seniors may be unaware o...
Better Buy in the Obesity Drug Race: Novo Nordisk or Eli Lilly?
Eli Lilly leads in next‑gen obesity drugs, while Novo Nordisk offers a cheaper, dividend‑paying alternative. Novo's steady insulin cash flows and new MASH bet could expand growth beyond its core diabe...